1. Amgen's dividend growth is strong with a 2.8% yield and consistent hikes since 2011, providing reliable income and a healthy payout ratio; 2. A robust R&D pipeline in obesity, cardiovascular, and oncology, along with strong financials, positions Amgen for long-term growth and stability; 3. Despite underperforming the S&P 500, Amgen's focus on high-growth areas and promising new drugs offers a compelling growth narrative; 4. Trading at a reasonable valuation, Amgen's combination of consistent dividend growth and promising R&D developments makes it a worthy pick for conservative investors.

1. EYLEA and Dupixent sales drive company revenue to new records; 2. R&D expenses are projected to reach $5 billion, but the business remains highly profitable; 3. Regeneron is liquid and solvent, but growth rates are falling; 4. The company's value appears overvalued according to quantitative analysis; 5. The author is holding the position for long-term growth and benefits.

1. Amgen's stock is currently fairly valued at 16.6x next year's earnings, supported by strong existing revenue growth and a diversified product portfolio. 2. New products like Blincyto, Tezspire, and Tepezza are driving significant revenue growth, validating recent share price appreciation. 3. MariTide, Amgen's GLP-1 candidate, offers potential upside due to its long-lasting effects and less frequent dosing, potentially addressing current market shortages.

1. A new research project, RauPE, aims to automate the production of stem cell therapies, making them accessible to a larger number of patients. 2. The project involves developing a robust automated expansion platform based on BioThrust's membrane stirrer bioreactor. 3. The goal is to create a scalable process for producing ciMSC-EV preparations that meets the certification requirements for medical products.

1. Researchers at Harvard University have developed a robot with a face made of living human skin, resembling a real-life T-1000. 2. The skin contains ligaments that provide flexibility and movement, similar to human skin. 3. This technology could have applications in the cosmetic industry for testing anti-aging products.